Brind.

Novartis and Memorial Sloan Kettering Cancer Center announce a clinical trial partnership and gain FDA approval for Pluvicto in prostate cancer.

2 reports, 2 independent Updated Aug 3

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Novartis and Memorial Sloan Kettering Cancer Center announce a clinical trial partnership and gain FDA approval for Pluvicto in prostate cancer.

Who's involved

What this event is mainly about

Novartis Memorial Sloan Kettering Cancer Center FDA

Keep exploring

The entities involved

Novartis
Swiss-American multinational pharmaceutical corporation
- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
- GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16
Memorial Sloan Kettering Cancer Center
cancer treatment and research institution in New York City, United States
- MoU signed between Memorial Sloan Kettering Cancer Center and a Ministry of Public Health for a new cancer treatment hospital.Wed 22:30
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Aug 3empr.com
Jul 31finanznachrichten.de